DE03722131T1 - Methode zur schmerzbekämpfung mit onkolytischen viren - Google Patents
Methode zur schmerzbekämpfung mit onkolytischen viren Download PDFInfo
- Publication number
- DE03722131T1 DE03722131T1 DE03722131T DE03722131T DE03722131T1 DE 03722131 T1 DE03722131 T1 DE 03722131T1 DE 03722131 T DE03722131 T DE 03722131T DE 03722131 T DE03722131 T DE 03722131T DE 03722131 T1 DE03722131 T1 DE 03722131T1
- Authority
- DE
- Germany
- Prior art keywords
- use according
- reovirus
- oncolytic virus
- administered
- analgesic
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 244000309459 oncolytic virus Species 0.000 title claims abstract 11
- 206010028980 Neoplasm Diseases 0.000 claims abstract 5
- 208000035269 cancer or benign tumor Diseases 0.000 claims abstract 5
- 239000003814 drug Substances 0.000 claims abstract 5
- 241000124008 Mammalia Species 0.000 claims abstract 4
- 241000702263 Reovirus sp. Species 0.000 claims 11
- 230000000202 analgesic effect Effects 0.000 claims 5
- 229940079593 drug Drugs 0.000 claims 3
- 241000702244 Orthoreovirus Species 0.000 claims 2
- 239000000730 antalgic agent Substances 0.000 claims 2
- OROGSEYTTFOCAN-DNJOTXNNSA-N codeine Chemical compound C([C@H]1[C@H](N(CC[C@@]112)C)C3)=C[C@H](O)[C@@H]1OC1=C2C3=CC=C1OC OROGSEYTTFOCAN-DNJOTXNNSA-N 0.000 claims 2
- BQJCRHHNABKAKU-KBQPJGBKSA-N morphine Chemical compound O([C@H]1[C@H](C=C[C@H]23)O)C4=C5[C@@]12CCN(C)[C@@H]3CC5=CC=C4O BQJCRHHNABKAKU-KBQPJGBKSA-N 0.000 claims 2
- 229940121367 non-opioid analgesics Drugs 0.000 claims 2
- 239000000014 opioid analgesic Substances 0.000 claims 2
- 229940005483 opioid analgesics Drugs 0.000 claims 2
- 239000007787 solid Substances 0.000 claims 2
- USSIQXCVUWKGNF-UHFFFAOYSA-N 6-(dimethylamino)-4,4-diphenylheptan-3-one Chemical compound C=1C=CC=CC=1C(CC(C)N(C)C)(C(=O)CC)C1=CC=CC=C1 USSIQXCVUWKGNF-UHFFFAOYSA-N 0.000 claims 1
- JAQUASYNZVUNQP-USXIJHARSA-N Levorphanol Chemical compound C1C2=CC=C(O)C=C2[C@]23CCN(C)[C@H]1[C@@H]2CCCC3 JAQUASYNZVUNQP-USXIJHARSA-N 0.000 claims 1
- XADCESSVHJOZHK-UHFFFAOYSA-N Meperidine Chemical compound C=1C=CC=CC=1C1(C(=O)OCC)CCN(C)CC1 XADCESSVHJOZHK-UHFFFAOYSA-N 0.000 claims 1
- BRUQQQPBMZOVGD-XFKAJCMBSA-N Oxycodone Chemical compound O=C([C@@H]1O2)CC[C@@]3(O)[C@H]4CC5=CC=C(OC)C2=C5[C@@]13CCN4C BRUQQQPBMZOVGD-XFKAJCMBSA-N 0.000 claims 1
- UQCNKQCJZOAFTQ-ISWURRPUSA-N Oxymorphone Chemical compound O([C@H]1C(CC[C@]23O)=O)C4=C5[C@@]12CCN(C)[C@@H]3CC5=CC=C4O UQCNKQCJZOAFTQ-ISWURRPUSA-N 0.000 claims 1
- 239000002246 antineoplastic agent Substances 0.000 claims 1
- 229960001736 buprenorphine Drugs 0.000 claims 1
- RMRJXGBAOAMLHD-IHFGGWKQSA-N buprenorphine Chemical compound C([C@]12[C@H]3OC=4C(O)=CC=C(C2=4)C[C@@H]2[C@]11CC[C@]3([C@H](C1)[C@](C)(O)C(C)(C)C)OC)CN2CC1CC1 RMRJXGBAOAMLHD-IHFGGWKQSA-N 0.000 claims 1
- 229960001113 butorphanol Drugs 0.000 claims 1
- IFKLAQQSCNILHL-QHAWAJNXSA-N butorphanol Chemical compound N1([C@@H]2CC3=CC=C(C=C3[C@@]3([C@]2(CCCC3)O)CC1)O)CC1CCC1 IFKLAQQSCNILHL-QHAWAJNXSA-N 0.000 claims 1
- 229960004126 codeine Drugs 0.000 claims 1
- 229940127089 cytotoxic agent Drugs 0.000 claims 1
- 229960004193 dextropropoxyphene Drugs 0.000 claims 1
- XLMALTXPSGQGBX-GCJKJVERSA-N dextropropoxyphene Chemical compound C([C@](OC(=O)CC)([C@H](C)CN(C)C)C=1C=CC=CC=1)C1=CC=CC=C1 XLMALTXPSGQGBX-GCJKJVERSA-N 0.000 claims 1
- 229960002428 fentanyl Drugs 0.000 claims 1
- PJMPHNIQZUBGLI-UHFFFAOYSA-N fentanyl Chemical compound C=1C=CC=CC=1N(C(=O)CC)C(CC1)CCN1CCC1=CC=CC=C1 PJMPHNIQZUBGLI-UHFFFAOYSA-N 0.000 claims 1
- 238000001794 hormone therapy Methods 0.000 claims 1
- OROGSEYTTFOCAN-UHFFFAOYSA-N hydrocodone Natural products C1C(N(CCC234)C)C2C=CC(O)C3OC2=C4C1=CC=C2OC OROGSEYTTFOCAN-UHFFFAOYSA-N 0.000 claims 1
- WVLOADHCBXTIJK-YNHQPCIGSA-N hydromorphone Chemical compound O([C@H]1C(CC[C@H]23)=O)C4=C5[C@@]12CCN(C)[C@@H]3CC5=CC=C4O WVLOADHCBXTIJK-YNHQPCIGSA-N 0.000 claims 1
- 229960001410 hydromorphone Drugs 0.000 claims 1
- 238000009169 immunotherapy Methods 0.000 claims 1
- 238000002347 injection Methods 0.000 claims 1
- 239000007924 injection Substances 0.000 claims 1
- 229960003406 levorphanol Drugs 0.000 claims 1
- 230000001394 metastastic effect Effects 0.000 claims 1
- 206010061289 metastatic neoplasm Diseases 0.000 claims 1
- 229960001797 methadone Drugs 0.000 claims 1
- 229960005181 morphine Drugs 0.000 claims 1
- 229960000805 nalbuphine Drugs 0.000 claims 1
- NETZHAKZCGBWSS-CEDHKZHLSA-N nalbuphine Chemical compound C([C@]12[C@H]3OC=4C(O)=CC=C(C2=4)C[C@@H]2[C@]1(O)CC[C@@H]3O)CN2CC1CCC1 NETZHAKZCGBWSS-CEDHKZHLSA-N 0.000 claims 1
- 229960002085 oxycodone Drugs 0.000 claims 1
- 229960005118 oxymorphone Drugs 0.000 claims 1
- VOKSWYLNZZRQPF-GDIGMMSISA-N pentazocine Chemical compound C1C2=CC=C(O)C=C2[C@@]2(C)[C@@H](C)[C@@H]1N(CC=C(C)C)CC2 VOKSWYLNZZRQPF-GDIGMMSISA-N 0.000 claims 1
- 229960005301 pentazocine Drugs 0.000 claims 1
- 229960000482 pethidine Drugs 0.000 claims 1
- 239000008194 pharmaceutical composition Substances 0.000 claims 1
- 238000001959 radiotherapy Methods 0.000 claims 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
- A61K35/66—Microorganisms or materials therefrom
- A61K35/76—Viruses; Subviral particles; Bacteriophages
- A61K35/765—Reovirus; Rotavirus
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/04—Centrally acting analgesics, e.g. opioids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/04—Antineoplastic agents specific for metastasis
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2720/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsRNA viruses
- C12N2720/00011—Details
- C12N2720/12011—Reoviridae
- C12N2720/12211—Orthoreovirus, e.g. mammalian orthoreovirus
- C12N2720/12232—Use of virus as therapeutic agent, other than vaccine, e.g. as cytolytic agent
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Chemical & Material Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Virology (AREA)
- Epidemiology (AREA)
- Neurosurgery (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Biomedical Technology (AREA)
- Neurology (AREA)
- Pain & Pain Management (AREA)
- Microbiology (AREA)
- Mycology (AREA)
- Rheumatology (AREA)
- Oncology (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US37867502P | 2002-05-09 | 2002-05-09 | |
| US378675P | 2002-05-09 | ||
| US44317703P | 2003-01-29 | 2003-01-29 | |
| US443177P | 2003-01-29 | ||
| PCT/CA2003/000674 WO2003094938A1 (en) | 2002-05-09 | 2003-05-07 | Method for reducing pain using oncolytic viruses |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| DE03722131T1 true DE03722131T1 (de) | 2005-09-15 |
Family
ID=29423642
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| DE03722131T Pending DE03722131T1 (de) | 2002-05-09 | 2003-05-07 | Methode zur schmerzbekämpfung mit onkolytischen viren |
| DE60322885T Expired - Lifetime DE60322885D1 (de) | 2002-05-09 | 2003-05-07 | Methode zur schmerzbekämpfung mit onkolytischen viren |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| DE60322885T Expired - Lifetime DE60322885D1 (de) | 2002-05-09 | 2003-05-07 | Methode zur schmerzbekämpfung mit onkolytischen viren |
Country Status (19)
| Country | Link |
|---|---|
| US (2) | US20040091458A1 (https=) |
| EP (1) | EP1505992B1 (https=) |
| JP (1) | JP5241059B2 (https=) |
| AR (1) | AR039986A1 (https=) |
| AT (1) | ATE404213T1 (https=) |
| AU (1) | AU2003229431B8 (https=) |
| BR (1) | BR0309825A (https=) |
| CA (1) | CA2484398C (https=) |
| DE (2) | DE03722131T1 (https=) |
| DK (1) | DK1505992T3 (https=) |
| ES (1) | ES2239928T3 (https=) |
| IL (1) | IL164695A (https=) |
| MX (1) | MXPA04011007A (https=) |
| NZ (1) | NZ536102A (https=) |
| PT (1) | PT1505992E (https=) |
| SI (1) | SI1505992T1 (https=) |
| TR (1) | TR200501460T3 (https=) |
| TW (1) | TWI316405B (https=) |
| WO (1) | WO2003094938A1 (https=) |
Families Citing this family (13)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| AUPQ425699A0 (en) | 1999-11-25 | 1999-12-23 | University Of Newcastle Research Associates Limited, The | A method of treating a malignancy in a subject and a pharmaceutical composition for use in same |
| AU2002953436A0 (en) | 2002-12-18 | 2003-01-09 | The University Of Newcastle Research Associates Limited | A method of treating a malignancy in a subject via direct picornaviral-mediated oncolysis |
| US10260049B2 (en) | 2005-08-01 | 2019-04-16 | Virocure, Inc. | Attenuated reovirus |
| US10668119B2 (en) | 2005-08-01 | 2020-06-02 | Virocure, Inc. | Attenuated reovirus |
| US10369171B2 (en) | 2007-03-13 | 2019-08-06 | Virocure, Inc. | Attenuated reoviruses for selection of cell populations |
| WO2008144067A1 (en) * | 2007-05-21 | 2008-11-27 | Board Of Regents, University Of Texas System | Methods and compositions for treatment of cancer using oncolytic rsv activity |
| US8450106B2 (en) * | 2007-10-17 | 2013-05-28 | The Ohio State University Research Foundation | Oncolytic virus |
| EP2296678A4 (en) * | 2008-05-27 | 2012-03-21 | Oncolytics Biotech Inc | MODULATION OF INTERSTITIAL PRESSURE AND ONCOLYTIC VIRUS RELIEF AND DISTRIBUTION |
| KR20100054358A (ko) * | 2008-11-14 | 2010-05-25 | 김재은 | 스틱 연고 |
| RU2554740C2 (ru) * | 2009-05-01 | 2015-06-27 | Апталис Фарматек, Инк. | Композиции перорально распадающихся таблеток, содержащие комбинации высоко- и низкодозовых лекарственных средств |
| EP2383577A1 (en) * | 2010-04-30 | 2011-11-02 | Deutsches Krebsforschungszentrum | Diagnostic method for predicting the response of a patient to chemovirotherapy or radiovirotherapy |
| JP6827467B2 (ja) | 2015-06-19 | 2021-02-10 | シルラジェン，インコーポレイテッド | ウイルス塞栓術のための組成物および方法 |
| EP3417866B1 (en) | 2016-02-16 | 2020-12-23 | Osaka University | Medicinal composition for treating fibrosis |
Family Cites Families (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5023252A (en) * | 1985-12-04 | 1991-06-11 | Conrex Pharmaceutical Corporation | Transdermal and trans-membrane delivery of drugs |
| US6110461A (en) * | 1997-08-13 | 2000-08-29 | Oncolytics Biotech Inc. | Reovirus for the treatment of neoplasia |
| US6136307A (en) * | 1997-08-13 | 2000-10-24 | Oncolytics Biotech Inc. | Reovirus for the treatment of cellular proliferative disorders |
| CN101618049A (zh) * | 1997-10-09 | 2010-01-06 | 威尔斯塔特生物公司 | 使用病毒来治疗赘生物 |
| US6428968B1 (en) * | 1999-03-15 | 2002-08-06 | The Trustees Of The University Of Pennsylvania | Combined therapy with a chemotherapeutic agent and an oncolytic virus for killing tumor cells in a subject |
| TWI289158B (en) * | 2000-08-10 | 2007-11-01 | Oncolytics Biotech Inc | Method of producing infectious reovirus |
-
2003
- 2003-05-07 JP JP2004503021A patent/JP5241059B2/ja not_active Expired - Lifetime
- 2003-05-07 EP EP03722131A patent/EP1505992B1/en not_active Expired - Lifetime
- 2003-05-07 WO PCT/CA2003/000674 patent/WO2003094938A1/en not_active Ceased
- 2003-05-07 TW TW092112420A patent/TWI316405B/zh not_active IP Right Cessation
- 2003-05-07 CA CA2484398A patent/CA2484398C/en not_active Expired - Lifetime
- 2003-05-07 NZ NZ536102A patent/NZ536102A/en unknown
- 2003-05-07 TR TR2005/01460T patent/TR200501460T3/xx unknown
- 2003-05-07 DE DE03722131T patent/DE03722131T1/de active Pending
- 2003-05-07 ES ES03722131T patent/ES2239928T3/es not_active Expired - Lifetime
- 2003-05-07 AU AU2003229431A patent/AU2003229431B8/en not_active Expired
- 2003-05-07 PT PT03722131T patent/PT1505992E/pt unknown
- 2003-05-07 SI SI200331415T patent/SI1505992T1/sl unknown
- 2003-05-07 DE DE60322885T patent/DE60322885D1/de not_active Expired - Lifetime
- 2003-05-07 MX MXPA04011007A patent/MXPA04011007A/es active IP Right Grant
- 2003-05-07 DK DK03722131T patent/DK1505992T3/da active
- 2003-05-07 BR BR0309825-7A patent/BR0309825A/pt not_active IP Right Cessation
- 2003-05-07 AT AT03722131T patent/ATE404213T1/de not_active IP Right Cessation
- 2003-05-08 US US10/431,580 patent/US20040091458A1/en not_active Abandoned
- 2003-05-08 AR ARP030101621A patent/AR039986A1/es unknown
-
2004
- 2004-10-19 IL IL164695A patent/IL164695A/en active IP Right Grant
-
2007
- 2007-06-01 US US11/809,714 patent/US20080081032A1/en not_active Abandoned
Also Published As
| Publication number | Publication date |
|---|---|
| IL164695A0 (en) | 2005-12-18 |
| WO2003094938A1 (en) | 2003-11-20 |
| CA2484398A1 (en) | 2003-11-20 |
| ES2239928T1 (es) | 2005-10-16 |
| JP5241059B2 (ja) | 2013-07-17 |
| AU2003229431A1 (en) | 2003-11-11 |
| US20040091458A1 (en) | 2004-05-13 |
| JP2005526124A (ja) | 2005-09-02 |
| US20080081032A1 (en) | 2008-04-03 |
| PT1505992E (pt) | 2008-10-06 |
| NZ536102A (en) | 2008-01-31 |
| TW200402305A (en) | 2004-02-16 |
| HK1070565A1 (en) | 2005-06-24 |
| AR039986A1 (es) | 2005-03-09 |
| EP1505992B1 (en) | 2008-08-13 |
| SI1505992T1 (sl) | 2009-02-28 |
| TWI316405B (en) | 2009-11-01 |
| ES2239928T3 (es) | 2009-02-16 |
| ATE404213T1 (de) | 2008-08-15 |
| BR0309825A (pt) | 2005-03-01 |
| MXPA04011007A (es) | 2005-02-14 |
| TR200501460T3 (tr) | 2005-06-21 |
| IL164695A (en) | 2010-12-30 |
| DK1505992T3 (da) | 2008-10-06 |
| DE60322885D1 (de) | 2008-09-25 |
| AU2003229431B2 (en) | 2008-01-17 |
| EP1505992A1 (en) | 2005-02-16 |
| CA2484398C (en) | 2014-01-21 |
| AU2003229431B8 (en) | 2009-07-02 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| DE68909056T2 (de) | Dosierform zum vermeiden von missbrauch. | |
| EP1515702B1 (de) | Gegen missbrauch gesicherte darreichungsform | |
| DE03722131T1 (de) | Methode zur schmerzbekämpfung mit onkolytischen viren | |
| EP2506712B1 (en) | Morphinan derivatives for the treatment of drug overdose | |
| US20030026838A1 (en) | Tamper-proof narcotic delivery system | |
| EP1007045B1 (en) | Topical application of opioid analgesic drugs such as morphine | |
| WO2012056402A2 (en) | Formulations and methods for attenuating respiratory depression induced by opioid overdose | |
| KR960703004A (ko) | 혈장 약물 농도의 신속한 초기 증가량을 시현하는 24시간 경구용 오피오이드 제형을 투여함으로써 통증을 치료하는 방법 | |
| EP0949925A2 (de) | Flache arzneizubereitung zur applikation und freisetzung von buprenorphin oder einer pharmakologisch vergleichbaren substanz in der mundhöhle und verfahren zu ihrer herstellung | |
| US8987290B2 (en) | Use of opioid formulations in needle-less drug delivery devices | |
| HUE026994T2 (en) | Liquid nasal spray containing low dose naltrexone | |
| DE2222039A1 (de) | Narkotische Arzneimittel | |
| DE19607395C2 (de) | Salze aus einem kationischen narkotischen Analgetikum mit einem anionischen nichtnarkotischen Analgetikum, Verfahren zu deren Herstellung und die diese Salze enthaltenden pharmazeutischen Präparate | |
| DE19749724A1 (de) | Verwendung einer Kombination aus Opioid und alpha-adrenergem Agonisten in Schmerzmitteln | |
| EP3079661B1 (de) | Naloxon-monopräparat und mehrschichttablette | |
| EP1535615A1 (en) | Composition for nasal absorption | |
| DE69625913T2 (de) | Inhibitor des erwerbs der abhängigkeit/resistenz gegen betäaubende analgetika | |
| EP1850836B1 (de) | Medikamentöse kombinationsbehandlung | |
| EP1121109B8 (de) | Zweiphasige Zusammensetzung mit Tramadol | |
| EP1420789B1 (de) | VERWENDUNG VON WIRKSTOFFEN MIT µ-OPIOID-REZEPTOR AGONISTISCHER WIRKUNG UND OPIOID-REZEPTOR ANTAGONISTISCHER WIRKUNG ALS KOMBINATIONSARZNEIMITTEL ZUR KREBSBEHANDLUNG | |
| EP1810678A1 (de) | Verwendung einer Kombination von Morphin und Naloxon zur Drogensubstitution | |
| US20190209540A1 (en) | Sublingual opioid formulations containing naloxone | |
| DE60316927T2 (de) | Verwendung von devazepide als schmerzmittel | |
| US12383550B2 (en) | Opioid overdose reversal mixtures | |
| DE102010048883A1 (de) | Verwendung von Buprenorphin zum Abususschutz von Opiat-Vollagonisten sowie entsprechende pharmazeutische Zusammensetzungen |